Filing Flows › Comparisons › SGHT vs XTNT
Sight Sciences vs Xtant Medical Holdings: SGHT and XTNT compared
Sight Sciences is the larger company: $24.9M of revenue in its latest quarter (Q3 2026) against $23.0M for Xtant Medical Holdings (Q2 2026). Sight Sciences is growing faster (+25% against -35% a year earlier). Sight Sciences is more profitable, with an operating margin of -24.6% against -39.8%.
Where the money goes: SGHT and XTNT
Sight Sciences (SGHT) · Q3 2026
Sight Sciences, Q3 2026: revenue $24.9M (+25% year over year), operating margin -24.6%, net loss $6.8M, operating cash flow −$2.4M. The chart follows the revenue to costs, profit and cash.
Xtant Medical Holdings (XTNT) · Q2 2026
Xtant Medical Holdings, Q2 2026: revenue $23.0M (-35% year over year), operating margin -39.8%, net loss $9.4M, operating cash flow −$7.3M. The chart follows the revenue to costs, profit and cash.
| Sight Sciences (SGHT) | Xtant Medical Holdings (XTNT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $24.9M | $23.0M |
| Revenue growth, Y/Y | +25% | -35% |
| Operating margin | -24.6% | -39.8% |
| Net earnings | −$6.8M | −$9.4M |
| Net margin | -27.3% | -40.9% |
| Operating cash flow | −$2.4M | −$7.3M |
Where the revenue comes from
Sight Sciences
- Surgical Glaucoma: $21.0M (84%)
- Dry Eye: $3.9M (16%)
Xtant Medical Holdings
- Orthobiologics: $17.4M (75%)
- Spinal Implant: $5.7M (25%)
Questions
Which is bigger, Sight Sciences or Xtant Medical Holdings?
Sight Sciences is the larger company: $24.9M of revenue in its latest quarter (Q3 2026) against $23.0M for Xtant Medical Holdings (Q2 2026).
Is Sight Sciences or Xtant Medical Holdings growing faster?
Sight Sciences is growing faster (+25% against -35% a year earlier).
Which is more profitable, Sight Sciences or Xtant Medical Holdings?
Sight Sciences is more profitable, with an operating margin of -24.6% against -39.8%.
More: Sight Sciences earnings · how Sight Sciences makes money · Xtant Medical Holdings earnings · how Xtant Medical Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.